🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).

    phase 2 small molecule active

    1 trial

  2. OPDIVO 10 mg/mL concentrate for solution for infusion., YERVOY 5 mg/ml concentrate for solution for infusion

    Tour Hekla

    Unresectable locally advanced or metastatic urothelial cancer

    phase 2 small molecule active

    1 trial

  3. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  4. OXALIPLATIN, AZD0901, CAPECITABINE, FLUOROURACIL, AZD7789, volrustomig, CAPECITABINE, CALCIUM FOLINATE, Rilvegostomig

    AstraZeneca AB

    Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB

    Arcus Biosciences

    Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies

    phase 2 small molecule active

    1 trial

  6. OXALIPLATIN, ETOPOSIDE, CISPLATIN, CALCIUM FOLINATE, CAPECITABINE, IRINOTECAN, PACLITAXEL, FLUOROURACIL, TRABECTEDIN, DOCETAXEL, IFOSFAMIDE, PACLITAXEL ALBUMIN-BOUND, DOXORUBICIN, MITOTANE, CARBOPLATIN, GEMCITABINE

    Ningbo Cancer Hospital

    Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanced or metastatic cancer

    phase 2 small molecule active

    1 trial

  7. Odomzo 200 mg hard capsules

    Fondazione Telethon ETS

    locally advanced basal cell carcinoma

    phase 2 small molecule active

    1 trial

  8. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  9. Orteronel 300mg BID

    Takeda

    Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors

    phase 2 small molecule terminated

    1 trial

  10. PACLITAXEL , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL , Lenvatinib, BEVACIZUMAB , CAPECITABINE , CARBOPLATIN , FLUOROURACIL , OXALIPLATIN , GEMCITABINE , CISPLATIN , MK-7684A, Lenvatinib

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  11. PACLITAXEL , Lenvatinib, MK-4830, FAMOTIDINE , KEYTRUDA 25 mg/mL concentrate for solution for infusion, PARACETAMOL , IRINOTECAN , -, Lenvatinib, -, MK-2870

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  12. PACLITAXEL, MaaT033, CISPLATIN, CARBOPLATIN, GEMCITABINE, PACLITAXEL, CISPLATIN, CARBOPLATIN, PACLITAXEL, PEMETREXED, GEMCITABINE, PEMETREXED, BEVACIZUMAB, PACLITAXEL, DOCETAXEL, PEMETREXED, DOCETAXEL, BEVACIZUMAB, GEMCITABINE, CISPLATIN, VINORELBINE, PACLITAXEL, CARBOPLATIN, VINORELBINE, CARBOPLATIN, VINORELBINE, PEMETREXED, VINORELBINE, DOCETAXEL, GEMCITABINE, LIBTAYO 350 mg concentrate for solution for infusion., PEMETREXED, PEMETREXED, PEMETREXED, CISPLATIN, PEMETREXED, DOCETAXEL

    The George Institute

    Advanced non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  13. PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  14. PC14586

    PMV Pharmaceuticals

    Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation

    phase 2 small molecule active

    1 trial

  15. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  16. PD-1 inhibitor

    The First People's Hospital of Lianyungang

    Advanced NSCLC

    phase 2 small molecule active

    1 trial

  17. PEGFILGRASTIM , Rinatabart Sesutecan

    Genmab A/S

    Locally advanced or metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. PEMBROLIZUMAB, ATEZOLIZUMAB, NIVOLUMAB, CEMIPLIMAB

    Fondazione Telethon ETS

    Unresectable or metastatic melanoma, Locally advanced or metastatic urothelial carcinoma, Locally advanced or metastatic non-small cell lung cancer (NSCLC), Untreated recurrent/metastatic head & neck sqamous cell carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  19. PEMBROLIZUMAB, PM54

    Lacuna Pharma Pty Ltd

    Advanced malignancies

    phase 2 small molecule active

    1 trial

  20. PF-07248144, FULVESTRANT ZENTIVA 250 mg, solution injectable en seringue préremplie, PF-07248144

    Ningbo Cancer Hospital

    Adult patients with advanced hormone receptor positive (HR+), HER2- breast cancer after at least a first line of endocrine therapy combined with CDK4/6 inhibitor in the metastatic setting

    phase 2 small molecule active

    1 trial

  21. PF-07850327 round

    Pfizer Australia Pty Ltd

    ADVANCED OR METASTATIC BREAST CANCER

    phase 2 small molecule active

    1 trial

  22. PF-08634404, YERVOY 5 mg/ml concentrate for solution for infusion

    Pfizer Australia Pty Ltd

    Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  23. PM14, IRINOTECAN

    Lacuna Pharma Pty Ltd

    Patients with Selected Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  24. PM8002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources